RVPH vs. CELU, IGMS, JMAC, MGX, ASRT, CABA, INMB, STRO, GNTA, and ARTV
Should you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Celularity (CELU), IGM Biosciences (IGMS), Maxpro Capital Acquisition (JMAC), Metagenomi (MGX), Assertio (ASRT), Cabaletta Bio (CABA), INmune Bio (INMB), Sutro Biopharma (STRO), Genenta Science (GNTA), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry.
Reviva Pharmaceuticals vs. Its Competitors
Reviva Pharmaceuticals (NASDAQ:RVPH) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.
Reviva Pharmaceuticals has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
In the previous week, Reviva Pharmaceuticals had 8 more articles in the media than Celularity. MarketBeat recorded 17 mentions for Reviva Pharmaceuticals and 9 mentions for Celularity. Celularity's average media sentiment score of 0.33 beat Reviva Pharmaceuticals' score of 0.17 indicating that Celularity is being referred to more favorably in the news media.
Reviva Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Reviva Pharmaceuticals' return on equity of 0.00% beat Celularity's return on equity.
Reviva Pharmaceuticals has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Reviva Pharmaceuticals currently has a consensus target price of $7.17, indicating a potential upside of 1,230.86%. Celularity has a consensus target price of $6.00, indicating a potential upside of 58.31%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Celularity.
63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 22.1% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Reviva Pharmaceuticals beats Celularity on 11 of the 15 factors compared between the two stocks.
Get Reviva Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Reviva Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RVPH) was last updated on 8/24/2025 by MarketBeat.com Staff
MarketBeat All Access